Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 5003-5010

  Pesta, Martin ^a   Kulda, Vlastimil ^a   Fiala, Ondrej ^a   Safranek, Jarmil ^a   Topolcan, Ondrej ^a   Krakorova, Gabriela ^a   Cerny, Radim ^a   Pesek, Milos ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adjuvant chemotherapy; BRCA1; DNA repair genes; ERCC1; NSCLC; Prognosis; RRM1

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; MESSENGER RNA; NAVELBINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SUBUNIT M1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84872661482     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Filipits M and Pirker R: Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer 74(3): 355-363, 2011.
2. Zhang L, Yang H and Xu J: Gene expression significance in personalized medicine of non-small cell lung cancer and gene expression analyzing platforms. Curr Drug Metab 12(5): 455-459, 2011.
3. Aggarwal C, Somaiah N and Simon GR: Biomarkers with predictive and prognostic function in non-small cell lung cancer: Ready for prime time? J Natl Compr Canc Netw 8(7): 822-832, 2010.
4. Carbone DP and Felip E: Adjuvant therapy in non-small cell lung cancer: Future treatment prospects and paradigms. Clin Lung Cancer 12(5): 261-271, 2011.
5. Smolle-Juettner FM, Maier A, Lindenmann J, Matzi V and Neubock N: Resection in stage I/II non-small cell lung cancer. Front Radiat Ther Oncol 42: 71-77, 2010.
6. Rosell R, Taron M, Alberola V, Massuti B and Felip E: Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 41(Suppl 1): S97-S102, 2003.
7. Rosell R, Taron M, Camps C and Lopez-Vivanco G: Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc) 39(10): 775-786, 2003.
8. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A and Simon G: RRM1 modulated in vitro and in vivoefficacy of gemcitabine and platinum in non-small cell lung cancer. J Clin Oncol 24(29): 4731-4737, 2006.
9. Su C, Zhou S, Zhang L, Ren S, Xu J, Zhang J, Lv M, Zhang J and Zhou C: ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol 28(4): 1411-1417, 2011.
10. Roy R, Chun J and Powell SN: BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 12(1): 68-78, 2011.
11. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG and Harkin DP: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63(19): 6221-6228, 2003.
12. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer, V.3.2011. Available at: http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf
13. Chen S, Zhang J, Wang R, Luo X and Chen H: The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70(1): 63-70, 2010.
14. Knez L, Sodja E, Kern I, Košnik M and Cufer T: Predictivevalue of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: A systematic review. Lung Cancer 72(3): 271-279, 2011.
15. Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB and Li XQ: Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer 69(1): 116-122, 2010.
16. Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW and Kim JH: The prognostic significance of ERCC1, BRCA1, XRCC1, and beta III-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 68(3): 478-483, 2010.
17. Li XQ, Li J, Shi SB, Chen P, Yu LC and Bao QL: Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. Int J Biol Markers 24(4): 230-237, 2009.
18. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T and Soria JC: DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983-991, 2006.
19. Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, Suehisa H, Kobayashi N, Aoe M, Yoshino T, Kiura K and Date H: ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small cell lung cancer. Lung Cancer 59(3): 377-384, 2008.
20. Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, Yano M and Fujii Y: Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 62(1): 105-112, 2008.
21. Bepler G, Olaussen KA, Vataire AL, Soria JC, Zheng Z, Dunant A, Pignon JP, Schell MJ, Fouret P, Pirker R, Filipits M and Brambilla E: ERCC1 and RRM1 in the International Adjuvant Lung Trial by automated quantitative in situ analysis. Am J Pathol 178(1): 69-78, 2011.
22. Jiang J, Liang X, Zhou X, Huang R, Chu Z and Zhan Q: ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: A meta-analysis. Mol Biol Rep 39(6): 6933-6942, 2012.
23. Simon GR, Sharma S, Cantor A, Smith P and Bepler G: ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127(3): 978-983, 2005.
24. Jung MK, Park KR, Oak CH, Jang TW, Chang HK and Park SD: Expression of ERCC1 in normal and tumor tissues in non-small cell lung cancer. J Thorac Oncol 2(8): S497, 2007.
25. Lenz HJ: Genetic markers for predicting disease and treatment outcome. Patent appplication publication US 2006/0115827 A1, 2006.
26. Ma W, Li W, Gao M and Li XN: Expression of ERCC1 mRNA and its impact on the prognosis of patients with non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 33(5): 371-374, 2007 (in Chinese).
27. Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW and Kim JH: ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 60(3): 401-407, 2008.
28. Coate LE, John T, Tsao MS and Shepherd FA: Molecular predictive and prognostic markers in non-small cell lung cancer. Lancet Oncol 10(10): 1001-1010, 2009.
29. Lee KH, Min HS, Lee SH, Kim DW, Chung DH, Kim YT, Heo DS, Kim JH and Sung SW: ERCC1 Expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. J Thorac Oncol 2(8): P2-079, 2007.